<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183232</url>
  </required_header>
  <id_info>
    <org_study_id>Gd T cell and lung Ca</org_study_id>
    <nct_id>NCT03183232</nct_id>
  </id_info>
  <brief_title>Safety and Efficiency of γδ T Cell Against Lung Cancer</brief_title>
  <official_title>γδ T Cell Immunotherapy for Treatment of Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuda Cancer Hospital, Guangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jinan University Guangzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fuda Cancer Hospital, Guangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, effects of γδT cells on human Lung Cancer in combination with tumor reducing
      surgery, for example, cryosurgery going to be investigated
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung tumor will be removed using tumor reducing surgery such as cryosurgery. PBMC of the
      patient will be separated from peripheral blood. After making them potential cancer killer γδ
      T Cell and DC-CIK, they will be infused to the patients as an immunotherapy treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2017</start_date>
  <completion_date type="Anticipated">June 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relief degree of tumors</measure>
    <time_frame>3 months</time_frame>
    <description>It will be evaluated by the Response Evaluation Criteria in Solid Tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progress free survival（PFS)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival（OS）</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryosurgery or IRE surgery</intervention_name>
    <description>Cryosurgery or IRE surgery will be used in local tumor</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>γδ T cell</intervention_name>
    <description>γδ T cells will be used against Lung Cancer</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>γδ T cells/ A Cryosurgery or IRE</intervention_name>
    <description>Combination γδ T cell and Cryosurgery or IRE surgery will be used in Lung Cancer</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age: 18-75 Karnofsky performance status &gt;50 Diagnosis with Lung Cancer based on histology
        or the current accepted radiological measures Classification
        tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ Will receive cryosurgery, IRE, gd T
        cells Life expectancy: Greater than 3 months Ability to understand the study protocol and a
        willingness to sign a written informed consent document

        Exclusion Criteria:

        Patients with other kinds of cancer History of coagulation disorders or anemia Patients
        with heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jibing Chen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biological treatment center in Fuda cancer hospital Guangzhou, Guangdong, China, 510000</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammed Alnaggar, Post Doc</last_name>
    <phone>0086-13826185510</phone>
    <email>dralnaggar@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biotherapy center in Fuda cancer hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510665</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moahmmed Alnaggar, Pos-Doc</last_name>
      <phone>+86-13826185510</phone>
      <email>dralnaggar@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy, γδ T Cell, Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

